188975-15-7

Usage

Explanation

This is the full chemical name of the compound, which describes its structure and composition.

Explanation

The common name for the compound, which is easier to remember and use in conversation.

Explanation

The primary industry in which 1-Piperidinecarboxylic acid, 4-(4-amino-2-fluorophenyl)-, 1,1-dimethylethyl ester is used, which is the development and production of medications.

Explanation

The class of compounds to which this chemical belongs, based on its structural features.

Explanation

The specific type of compound, which is derived from an ester functional group.

Explanation

The compound exhibits strong biological activity, meaning it has a significant effect on biological systems.

Explanation

The primary enzyme that the compound inhibits, which is involved in glucose metabolism.

Explanation

The compound's ability to inhibit DPP-4 makes it a potential candidate for treating type 2 diabetes and other related metabolic disorders.

Explanation

The compound has shown the ability to inhibit other biological targets, making it a versatile molecule with potential applications in the development of new drugs for various conditions.

Industry

Pharmaceutical

Chemical class

Piperidinecarboxylic acids

Type

Ester derivative

Biological activity

Potent

Target enzyme

Dipeptidyl peptidase-4 (DPP-4)

Potential treatment

Type 2 diabetes and metabolic disorders

Additional inhibitory properties

Other biological targets

Upstream product

• 185331-69-5 1-bromo-2-fluoro-4-nitrobenzene 
• 1373420-25-7 tert-butyl 4-(2-fluoro-4-nitrophenyl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 656-65-5 3-fluoro-4-bromophenylamine 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 

Downstream Products

• 1428759-17-4 C₂₉H₂₇ClFN₇O₂ 
• 1566584-53-9 tert-butyl 4-(4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-fluorophenyl)piperidine-1-carboxylate 
• 1566584-54-0 C₃₂H₃₂F₄N₄O₄ 
• 1566584-55-1 tert-butyl 4-(2-fluoro-4-((4-(2-(2-methoxy-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperidine-1-carboxylate 
• 1566584-56-2 tert-butyl 4-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-fluorophenyl)piperidine-1-carboxylate 
• 1566583-87-6 2-(2-(2-(2-((3-fluoro-4-(piperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1566583-88-7 2-(2-(2-(2-((3-fluoro-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 

Relevant academic research and scientific papers

COMPOUNDS FOR TARGETED DEGRADATION OF BRD9

BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

BRAF DEGRADERS

Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

VEGFR3 INHIBITORS

This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.